Companies Harmony Biosciences Holdings, Inc.
Harmony Biosciences (HRMY): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Harmony Biosciences Holdings, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers22nd pct.Of 9 peer CEOs
CEO pay, last three years
- $4,450,294FY2023
- $7,145,170FY2024
- $7,899,535FY2025
CEO total pay was $7,899,535 in fiscal 2025, up from $7,145,170 in fiscal 2024.
FY2025: salary $743,600 · bonus $0 · stock awards $1,976,520 · option awards $4,599,000
Executives and directors
Adam Zaeske · CCOAndrew Serafin · ExecutiveJeffrey Dayno · CEOJeffrey Dierks · CCOKumar Budur · EVPSandip Kapadia · CFOAndreas Wicki · Independent DirectorAntonio Gracias · Independent DirectorGary Sender · Independent DirectorGeno Germano · Independent DirectorJeffrey S. Aronin · Chair of the BoardJuan A. Sabater · Independent DirectorLinda Szyper · Independent DirectorPeter Anastasiou · Former director (through FY2025)R. Mark Graf · Independent DirectorRon Philip · Independent DirectorTroy Ignelzi · Independent Director
Frequently asked questions
Who was the highest-paid executive at Harmony Biosciences Holdings, Inc. in fiscal 2025?
As disclosed, Jeffrey Dayno (President and Chief Executive Officer) was the highest-paid executive at Harmony Biosciences Holdings, Inc. in fiscal 2025, with total compensation of $7,899,535.
How does Harmony Biosciences Holdings, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Jeffrey Dayno's total compensation ranked at the 22nd percentile of Harmony Biosciences Holdings, Inc.'s disclosed peer group.
What is Harmony Biosciences Holdings, Inc.'s CEO-to-median employee pay ratio?
As disclosed, Harmony Biosciences Holdings, Inc.'s CEO-to-median employee pay ratio was 26:1.
How did shareholders vote on Harmony Biosciences Holdings, Inc.'s executive compensation?
As disclosed, 71.83% of shareholders supported Harmony Biosciences Holdings, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Harmony Biosciences Holdings, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Harmony Biosciences Holdings, Inc. reported total board compensation of $510,126 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Jeffrey Dayno | $743,600 | $0 | $1,976,520 | $4,599,000 | $558,000 | $0 | $22,415 | $7,899,535 |
| President and Chief Executive Officer | ||||||||
| Adam Zaeske | 376,923 | 200,000 | 852,000 | 1,866,000 | 189,041 | 0 | 180,264 | 3,664,228 |
| Executive Vice President and Chief Commercial Officer | ||||||||
| Sandip Kapadia | 522,834 | 0 | 718,389 | 1,692,688 | 248,346 | 0 | 22,062 | 3,204,319 |
| Executive Vice President, Chief Financial Officer and Chief Administrative Officer | ||||||||
| Jeffrey Dierks | 132,263 | 0 | 511,235 | 1,205,960 | 0 | 0 | 497,487 | 2,346,945 |
| Former Executive Vice President and Chief Commercial Officer | ||||||||
| Kumar Budur | 598,000 | 0 | 404,807 | 955,570 | 299,000 | 0 | 22,062 | 2,279,439 |
| Executive Vice President and Chief Medical and Scientific Officer | ||||||||
| Andrew Serafin | 439,208 | 0 | 395,304 | 932,575 | 219,605 | 0 | 22,585 | 2,009,277 |
| Executive Vice President and Chief Strategy Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Jeffrey Dayno | $7,899,535 | $7,145,170 | $4,450,294 | ↑ +754,365 |
| Adam Zaeske | 3,664,228 | — | — | — |
| Sandip Kapadia | 3,204,319 | 3,070,401 | 5,580,524 | ↑ +133,918 |
| Jeffrey Dierks | 2,346,945 | 2,470,910 | 5,597,749 | ↓ −123,965 |
| Kumar Budur | 2,279,439 | 5,732,705 | 760,813 | ↓ −3,453,266 |
| Andrew Serafin | 2,009,277 | 2,087,422 | 647,426 | ↓ −78,145 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The key objectives of our executive compensation program are to attract, motivate, and reward leaders who create an inclusive and diverse environment and have the skills and experience necessary to successfully execute on our strategic plan to maximize stockholder value. Our executive compensation program is designed to: Attract and retain talented and experienced executives in a competitive and dynamic market; Motivate our NEOs to help the Company achieve the best possible financial and operational results; and Align the long-term interests of our NEOs with those of our stockholders.
| CEO STI target (% of salary) | 75% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pay Governance |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Adam Zaeske | RSU | 2025-04-07 | — | — | 30,000 | — | $852,000 |
| Kumar Budur | RSU | 2025-01-25 | — | — | 10,650 | — | 404,807 |
| Andrew Serafin | OPTION | 2025-01-25 | — | — | 36,500 | — | 932,575 |
| Andrew Serafin | RSU | 2025-01-25 | — | — | 10,400 | — | 395,304 |
| Jeffrey Dayno | RSU | 2025-01-25 | — | — | 52,000 | — | 1,976,520 |
| Jeffrey Dierks | OPTION | 2025-01-25 | — | — | 47,200 | — | 1,205,960 |
| Sandip Kapadia | RSU | 2025-01-25 | — | — | 18,900 | — | 718,389 |
| Jeffrey Dierks | RSU | 2025-01-25 | — | — | 13,450 | — | 511,235 |
| Adam Zaeske | OPTION | 2025-04-07 | — | — | 100,000 | — | 1,866,000 |
| Jeffrey Dayno | OPTION | 2025-01-25 | — | — | 180,000 | — | 4,599,000 |
| Sandip Kapadia | OPTION | 2025-01-25 | — | — | 66,250 | — | 1,692,688 |
| Kumar Budur | OPTION | 2025-01-25 | — | — | 37,400 | — | 955,570 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Adam Zaeske | $852,000 | $0 | $1,866,000 | 0.0% |
| Kumar Budur | 404,807 | 0 | 955,570 | 0.0% |
| Andrew Serafin | 395,304 | 0 | 932,575 | 0.0% |
| Jeffrey Dayno | 1,976,520 | 0 | 4,599,000 | 0.0% |
| Jeffrey Dierks | 511,235 | 0 | 1,205,960 | 0.0% |
| Sandip Kapadia | 718,389 | 0 | 1,692,688 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Kumar Budur | RSU | 6,563 | — | $245,587 |
| Andrew Serafin | RSU | 7,500 | — | 280,650 |
| Andrew Serafin | RSU | 10,400 | — | 389,168 |
| Kumar Budur | RSU | 10,650 | — | 398,523 |
| Sandip Kapadia | RSU | 11,438 | — | 428,010 |
| Sandip Kapadia | RSU | 18,900 | — | 707,238 |
| Kumar Budur | Option | 23,906 | 30.69 | — |
| Andrew Serafin | Option | 26,859 | 30.69 | — |
| Adam Zaeske | RSU | 30,000 | — | 1,122,600 |
| Jeffrey Dayno | RSU | 31,500 | — | 1,178,730 |
| Andrew Serafin | Option | 36,500 | 38.01 | — |
| Kumar Budur | Option | 37,400 | 38.01 | — |
| Sandip Kapadia | Option | 41,766 | 30.69 | — |
| Sandip Kapadia | RSU | 45,000 | — | 1,683,900 |
| Kumar Budur | Option | 46,875 | 30.27 | — |
| Jeffrey Dayno | Option | 46,875 | 35.56 | — |
| Jeffrey Dayno | RSU | 52,000 | — | 1,945,840 |
| Kumar Budur | RSU | 56,250 | — | 2,104,875 |
| Sandip Kapadia | Option | 66,250 | 38.01 | — |
| Kumar Budur | Option | 75,000 | 49.27 | — |
| Jeffrey Dayno | Option | 113,766 | 30.69 | — |
| Jeffrey Dayno | Option | 180,000 | 38.01 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Ron PhilipIndependent · Audit · Nominating and Corporate Governance | $50,438 | $0 | $610,581 | $0 | $0 | $661,019 |
| Gary SenderIndependent · Audit (Chair) · Compensation | 82,000 | 0 | 314,401 | 0 | 0 | 396,401 |
| Antonio GraciasIndependent · Compensation (Chair) | 67,500 | 0 | 314,401 | 0 | 0 | 381,901 |
| R. Mark GrafIndependent · Audit | 60,250 | 0 | 314,401 | 0 | 0 | 374,651 |
| Juan A. SabaterIndependent · Nominating and Corporate Governance (Chair) | 60,250 | 0 | 314,401 | 0 | 0 | 374,651 |
| Peter AnastasiouIndependent · Departed during FY | 58,250 | 0 | 314,401 | 0 | 0 | 372,651 |
| Linda SzyperIndependent · Nominating and Corporate Governance | 53,938 | 0 | 314,401 | 0 | 0 | 368,339 |
| Jeffrey S. AroninNot independent · Board Chair | 77,500 | 0 | — | 0 | 0 | 77,500 |
| Geno GermanoIndependent · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
| Troy IgnelziIndependent · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
| Andreas WickiIndependent · Audit · Compensation | 0 | 0 | 0 | 0 | 0 | 0 |
| Jeffrey M. DaynoEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $300,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 12,000 |
| Stock ownership guideline | $2 |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $510,126 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $510,126 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Harmony Biosciences as a peer
Companies that benchmark against HRMY
13 companies name HRMY as a compensation peer
- ACADIA PHARMACEUTICALS INCACADFY2025
- ADMA BIOLOGICS, INC.ADMAFY2025
- AMICUS THERAPEUTICS, INC.FOLDFY2024
- AVADEL PHARMACEUTICALS PLCAVDLFY2024
- BIOCRYST PHARMACEUTICALS INCBCRXFY2025
- CATALYST PHARMACEUTICALS, INC.CPRXFY2024
- DYNAVAX TECHNOLOGIES CORPDVAXFY2024
- Kiniksa Pharmaceuticals International, plcKNSAFY2025
- SIGA TECHNOLOGIES INCSIGAFY2025
- SUPERNUS PHARMACEUTICALS, INC.SUPNFY2025
- Travere Therapeutics, Inc.TVTXFY2025
Each company listed discloses HRMY in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named HRMY in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
ALKS AlkermesAXSM AxsomeNBIX Neurocrine BiosciencesSAGE Sage TherapeuticsITCI Intra-CellularIONS IonisSUPN SupernusJAZZ Jazz PharmaceuticalsAKR Acadia
Peer reciprocity
The companies Harmony Biosciences Holdings, Inc. names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Jazz Pharmaceuticals | 2025 | Renee Gala | $1,003,269 | $16,138,433 | $0 | $1,980,000 | $19,151,558 |
| 2 | Supernus | 2025 | Jack Khattar | 1,036,000 | 6,535,029 | 7,031,545 | 846,930 | 15,501,557 |
| 3 | Neurocrine Biosciences | 2025 | Kyle Gano | 920,000 | 5,750,023 | 5,750,006 | 0 | 13,448,935 |
| 4 | Ionis | 2025 | Brett Monia | 1,051,776 | 8,444,838 | 1,438,105 | 0 | 13,350,777 |
| 5 | Axsome | 2025 | Herriot Tabuteau | 835,000 | 5,533,554 | 2,833,237 | 876,750 | 10,283,492 |
| 6 | Intra-Cellular | 2023 | Sharon Mates | 891,653 | 7,749,984 | 0 | 0 | 10,086,413 |
| 7 | Alkermes | 2025 | Richard Pops | 1,250,769 | 0 | 5,020,812 | 1,626,000 | 7,915,081 |
| 8 | Harmony Biosciences Holdings, Inc. | 2025 | Jeffrey Dayno | 743,600 | 1,976,520 | 4,599,000 | 558,000 | 7,899,535 |
| 9 | Sage Therapeutics | 2024 | Barry Greene | 830,712 | 3,164,364 | 2,669,263 | 431,970 | 7,112,589 |
| 10 | Acadia | 2025 | Kenneth Bernstein | 850,000 | 3,574,544 | 0 | 2,486,898 | 6,922,230 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Harmony Biosciences Holdings, Inc. | 100% | not disclosed | not disclosed | Pay Governance |
| Acadia | not disclosed | LTIP Units 100 | Yes — Relative TSR vs. Nareit Shopping Center Index | Ferguson Partners Consulting (FPC) |
| Alkermes | 130% | PRSU 53 · RSU 24 · Option 23 | Yes — Relative Total Shareholder Return (TSR) | Alpine Rewards LLC |
| Axsome | 150% | RSU 33 · Options 33 · PSU 33 | No | Frederic W. Cook & Co., Inc. |
| Intra-Cellular | not disclosed | RSU 75 · PRSU 25 | Yes — Total Stockholder Return (TSR) of Company stock relative to the TSR of companies in the Nasdaq Biotechnology Index | Aon Consulting, Inc. |
| Ionis | not disclosed | PRSU 40 · Option 30 · RSU 30 | Yes — Relative TSR | Aon |
| Jazz Pharmaceuticals | 150% | PSU 50 · RSU 50 | Yes — Relative TSR | Aon |
| Neurocrine Biosciences | 105% | Option 50 · PRSU 30 · RSU 20 | No | Frederic W. Cook & Co., Inc. |
| Sage Therapeutics | 80% | not disclosed | Yes — TSR milestones / Relative TSR vs. Nasdaq Biotechnology Index | Alpine Rewards |
| Supernus | not disclosed | not disclosed | No | Aon |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-14 | 33,249,862 | 13,042,898 | 194,545 | 71.83% | Passed |
| 2023 | 2023-05-25 | 51,543,958 | 1,252,960 | 406,969 | 97.63% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-05-14 | 71.83%a |
| 2023 | 2023-05-25 | 97.63%b |
a. Approved under the standard stated in the filing — “Abstentions will have no effect on the outcome of this proposal.”.
b. Approved under the standard stated in the filing — “Abstentions will have no effect on the outcome of this proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 26 : 1 |
|---|---|
| CEO total compensation | $7,899,535 |
| Median employee compensation | $303,481 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Adam Zaeske | Chief Commercial Officer | 2026-04-07 | D | 7,500 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Adam Zaeske | Chief Commercial Officer | 2026-04-07 | D | 3,173 | 28 | 87,638 | Common | Form 4 ↗ |
| Adam Zaeske | Chief Commercial Officer | 2026-04-07 | A | 7,500 | 0 | 0 | Common | Form 4 ↗ |
| Glenn Reicin | Chief Financial Officer | 2026-04-14 | A | 164,309 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-05-01 | D | 18,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-05-01 | A | 18,750 | 0 | 0 | Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-05-01 | D | 8,882 | 32 | 282,714 | Common | Form 4 ↗ |
| Geno Germano | Director | 2026-05-14 | A | 21,231 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ron Philip | Director | 2026-05-14 | A | 21,872 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gary Sender | Director | 2026-05-14 | A | 21,872 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| R. Mark Graf | Director | 2026-05-14 | A | 21,872 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Linda Szyper | Director | 2026-05-14 | A | 21,872 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Juan A. Sabater | Director | 2026-05-14 | A | 21,872 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-04 | D | 5,500 | 42 | 230,911 | Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-08 | A | 12,200 | 31 | 374,418 | Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-08 | D | 22,954 | 43 | 989,350 | Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-08 | D | 10,754 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-08 | A | 10,754 | 30 | 325,524 | Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-08 | D | 12,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-08 | D | 4,500 | 42 | 190,114 | Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-08 | D | 1,000 | 43 | 42,795 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-09-16 | — | 1,800 | — | — | 1 insider, 2 accrual rows | ||
| Kumar Budur | Chief Medical Officer | 2026-09-16 | D | 1,800 | 43 | 77,426 | Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-16 | A | 900 | 30 | 27,243 | Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-16 | A | 900 | 31 | 27,621 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-09-17 | — | 800 | — | — | 1 insider, 2 accrual rows | ||
| Kumar Budur | Chief Medical Officer | 2026-09-17 | A | 400 | 30 | 12,108 | Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-17 | A | 400 | 31 | 12,276 | Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-17 | D | 800 | 43 | 34,400 | Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-18 | A | 25,446 | 30 | 770,250 | Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-18 | D | 25,446 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-18 | D | 35,852 | 43 | 1,543,590 | Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-18 | A | 10,406 | 31 | 319,360 | Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-18 | D | 10,406 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 36 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Adam Zaeske | Chief Commercial Officer | 2026-04-07 | D | 7,500 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Adam Zaeske | Chief Commercial Officer | 2026-04-07 | D | 3,173 | 28 | 87,638 | Common | Form 4 ↗ |
| Adam Zaeske | Chief Commercial Officer | 2026-04-07 | A | 7,500 | 0 | 0 | Common | Form 4 ↗ |
| Glenn Reicin | Chief Financial Officer | 2026-04-14 | A | 164,309 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-05-01 | D | 18,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-05-01 | A | 18,750 | 0 | 0 | Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-05-01 | D | 8,882 | 32 | 282,714 | Common | Form 4 ↗ |
| Geno Germano | Director | 2026-05-14 | A | 21,231 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ron Philip | Director | 2026-05-14 | A | 21,872 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gary Sender | Director | 2026-05-14 | A | 21,872 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| R. Mark Graf | Director | 2026-05-14 | A | 21,872 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Linda Szyper | Director | 2026-05-14 | A | 21,872 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Juan A. Sabater | Director | 2026-05-14 | A | 21,872 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-04 | D | 5,500 | 42 | 230,911 | Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-08 | A | 12,200 | 31 | 374,418 | Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-08 | D | 22,954 | 43 | 989,350 | Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-08 | D | 10,754 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-08 | A | 10,754 | 30 | 325,524 | Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-08 | D | 12,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-08 | D | 4,500 | 42 | 190,114 | Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-08 | D | 1,000 | 43 | 42,795 | Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-16 | D | 900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-16 | D | 900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-16 | D | 1,800 | 43 | 77,426 | Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-16 | A | 900 | 30 | 27,243 | Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-16 | A | 900 | 31 | 27,621 | Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-17 | D | 400 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-17 | D | 400 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-17 | A | 400 | 30 | 12,108 | Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-17 | A | 400 | 31 | 12,276 | Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-17 | D | 800 | 43 | 34,400 | Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-18 | A | 25,446 | 30 | 770,250 | Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-18 | D | 25,446 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-18 | D | 35,852 | 43 | 1,543,590 | Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-18 | A | 10,406 | 31 | 319,360 | Common | Form 4 ↗ |
| Kumar Budur | Chief Medical Officer | 2026-09-18 | D | 10,406 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Sources (84 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Jeffrey Dayno. DEF 14A, filed 2026-04-03. Section “Summary Compensation Table”. As printed: 7,899,535. View filing ↗
- Section 01, Adam Zaeske. DEF 14A, filed 2026-04-03. Section “Summary Compensation Table”. As printed: 3,664,228. View filing ↗
- Section 01, Sandip Kapadia. DEF 14A, filed 2026-04-03. Section “Summary Compensation Table”. As printed: 3,204,319. View filing ↗
- Section 01, Jeffrey Dierks. DEF 14A, filed 2026-04-03. Section “Summary Compensation Table”. As printed: 2,346,945. View filing ↗
- Section 01, Kumar Budur. DEF 14A, filed 2026-04-03. Section “Summary Compensation Table”. As printed: 2,279,439. View filing ↗
- Section 01, Andrew Serafin. DEF 14A, filed 2026-04-03. Section “Summary Compensation Table”. As printed: 2,009,277. View filing ↗
- Section 03, Adam Zaeske RSU. DEF 14A, filed 2026-04-03. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Kumar Budur RSU. DEF 14A, filed 2026-04-03. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Andrew Serafin OPTION. DEF 14A, filed 2026-04-03. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Andrew Serafin RSU. DEF 14A, filed 2026-04-03. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Jeffrey Dayno RSU. DEF 14A, filed 2026-04-03. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Jeffrey Dierks OPTION. DEF 14A, filed 2026-04-03. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Sandip Kapadia RSU. DEF 14A, filed 2026-04-03. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Jeffrey Dierks RSU. DEF 14A, filed 2026-04-03. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Adam Zaeske OPTION. DEF 14A, filed 2026-04-03. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Jeffrey Dayno OPTION. DEF 14A, filed 2026-04-03. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Sandip Kapadia OPTION. DEF 14A, filed 2026-04-03. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Kumar Budur OPTION. DEF 14A, filed 2026-04-03. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-03. Section “CEO Pay Ratio”. As printed: 26 : 1. View filing ↗
- Section 08, Ron Philip. DEF 14A, filed 2026-04-03. Section “Director Compensation”. As printed: 661,019. View filing ↗
- Section 08, Gary Sender. DEF 14A, filed 2026-04-03. Section “Director Compensation”. As printed: 396,401. View filing ↗
- Section 08, Antonio Gracias. DEF 14A, filed 2026-04-03. Section “Director Compensation”. As printed: 381,901. View filing ↗
- Section 08, R. Mark Graf. DEF 14A, filed 2026-04-03. Section “Director Compensation”. As printed: 374,651. View filing ↗
- Section 08, Juan A. Sabater. DEF 14A, filed 2026-04-03. Section “Director Compensation”. As printed: 374,651. View filing ↗
- Section 08, Peter Anastasiou. DEF 14A, filed 2026-04-03. Section “Director Compensation”. As printed: 372,651. View filing ↗
- Section 08, Linda Szyper. DEF 14A, filed 2026-04-03. Section “Director Compensation”. As printed: 368,339. View filing ↗
- Section 08, Jeffrey S. Aronin. DEF 14A, filed 2026-04-03. Section “Director Compensation”. As printed: 77,500. View filing ↗
- Section 08, Geno Germano. DEF 14A, filed 2026-04-03. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Troy Ignelzi. DEF 14A, filed 2026-04-03. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Andreas Wicki. DEF 14A, filed 2026-04-03. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Jeffrey M. Dayno. DEF 14A, filed 2026-04-03. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Adam Zaeske 2026-04-07. Form 4, filed 2026-04-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Zaeske 2026-04-07. Form 4, filed 2026-04-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Zaeske 2026-04-07. Form 4, filed 2026-04-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Glenn Reicin 2026-04-14. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kumar Budur 2026-05-01. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kumar Budur 2026-05-01. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kumar Budur 2026-05-01. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Geno Germano 2026-05-14. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ron Philip 2026-05-14. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gary Sender 2026-05-14. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, R. Mark Graf 2026-05-14. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Linda Szyper 2026-05-14. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Juan A. Sabater 2026-05-14. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kumar Budur 2026-09-04. Form 4, filed 2026-09-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kumar Budur 2026-09-08. Form 4, filed 2026-09-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kumar Budur 2026-09-08. Form 4, filed 2026-09-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kumar Budur 2026-09-08. Form 4, filed 2026-09-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kumar Budur 2026-09-08. Form 4, filed 2026-09-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kumar Budur 2026-09-08. Form 4, filed 2026-09-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kumar Budur 2026-09-08. Form 4, filed 2026-09-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kumar Budur 2026-09-08. Form 4, filed 2026-09-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kumar Budur 2026-09-16. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kumar Budur 2026-09-16. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kumar Budur 2026-09-16. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kumar Budur 2026-09-16. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kumar Budur 2026-09-16. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kumar Budur 2026-09-17. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kumar Budur 2026-09-17. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kumar Budur 2026-09-17. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kumar Budur 2026-09-17. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kumar Budur 2026-09-17. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kumar Budur 2026-09-18. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kumar Budur 2026-09-18. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kumar Budur 2026-09-18. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kumar Budur 2026-09-18. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kumar Budur 2026-09-18. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-05-14. Item 5.07 · say-on-pay result. As reported: 71.83% (votes for as printed: 33,249,862). View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-05-26. Item 5.07 · say-on-pay result. As reported: 97.63% (votes for as printed: 51,543,958). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 510,126 + equity 0 + all other 0 = 510,126, summed across the director compensation table rows.
- Jazz Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-06-08. CEO total compensation as printed in Jazz Pharmaceuticals's own proxy. As printed: 19,151,558. View filing ↗
- Supernus, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Supernus's own proxy. As printed: 15,501,557. View filing ↗
- Neurocrine Biosciences, Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Neurocrine Biosciences's own proxy. As printed: 13,448,935. View filing ↗
- Ionis, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Ionis's own proxy. As printed: 13,350,777. View filing ↗
- Axsome, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Axsome's own proxy. As printed: 10,283,492. View filing ↗
- Intra-Cellular, Section 10b CEO total. DEF 14A, filed 2024-04-29. CEO total compensation as printed in Intra-Cellular's own proxy. As printed: 10,086,413. View filing ↗
- Alkermes, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Alkermes's own proxy. As printed: 7,915,081. View filing ↗
- Harmony Biosciences Holdings, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-03. CEO total compensation as printed in Harmony Biosciences Holdings, Inc.'s own proxy. As printed: 7,899,535. View filing ↗
- Sage Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Sage Therapeutics's own proxy. As printed: 7,112,589. View filing ↗
- Acadia, Section 10b CEO total. DEF 14A, filed 2026-03-31. CEO total compensation as printed in Acadia's own proxy. As printed: 6,922,230. View filing ↗
- Section 10a, Sage Therapeutics reciprocity. DEF 14A. Sage Therapeutics names Harmony Biosciences Holdings, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Supernus reciprocity. DEF 14A. Supernus names Harmony Biosciences Holdings, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗